Emerging research suggests a powerful partnership between the GLP-1/GIP receptor agonist, another novel drug , and NAD+ . While tirzepatide and retatrutide have demonstrated remarkable results in addressing type 2 diabetes and facilitating body composition changes, evidence now points to Tirzepatide 40mg that bolstering metabolic activity with this